Coherus Oncology (CHRS) Change in Account Payables (2013 - 2026)

Coherus Oncology has reported Change in Account Payables for 14 years, with the latest figure at $2.6 million in Q1 2026.

• Quarterly Change in Account Payables fell 80.34% year-over-year to $2.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$30.0 million (down 453.84% YoY) and the FY2025 annual result came in at -$19.6 million, down 396.6% from the prior year.
• Change in Account Payables improved to $2.6 million in Q1 2026 per CHRS's latest filing, from -$5.1 million in the prior quarter.
• Over five years, Change in Account Payables peaked at $39.5 million in Q2 2024 and troughed at -$50.4 million in Q3 2024.
• A 5-year average of -$101058.8 and a median of $1.6 million in 2022 frame the typical range for Change in Account Payables.
• The sharpest annual moves came in 2022 and 2024: Change in Account Payables jumped 2243.35% in 2022, then sank 845.04% in 2024.
• Over 5 years, Change in Account Payables stood at $1.6 million in 2022, then slumped by 149.03% to -$785000.0 in 2023, then soared by 907.9% to $6.3 million in 2024, then sank by 180.23% to -$5.1 million in 2025, then soared by 150.39% to $2.6 million in 2026.
• According to Business Quant data, Change in Account Payables over the past three periods registered $2.6 million, -$5.1 million, and -$15.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.